Pulnovo Medical Announces Dr. Krishna Sudhir Joins Scientific Advisory Board
15 Jun 2022
SHANGHAI, June 15, 2022 /PRNewswire/ -- Pulnovo Medical Limited, a globally recognized OTM innovation platform, recently announced that Dr. Krishna Sudhir has officially joined the Pulnovo Medical Scientific Advisory Board. Dr. Krishna Sudhir will provide scientific guidance and take an important part in the innovation and internationalization of Pulnovo Medical's technology platforms and R&D portfolio.
Preview
Source: PRNewswire
Dr. Sudhir is a distinguished expert in the cardiovascular field with over 20 years of international leadership experience in technology development, medical discovery, and commercialization in the medical device field. He is currently serving as a
Consulting Professor of Medicine at the Center for Cardiovascular Technology at
Stanford University . Prior to that, Dr. Sudhir was the
Global Vice President of Medical Affairs for Abbott's Global Cardiovascular Division and lead the medical research and development departments at
Abbott Vascular for more than 15 years. Dr Sudhir has also worked with the
University of California, San Francisco,
Alfred Heart Center,
and
Baker IDI Heart and
Diabetes Institute, where he focused on cardiac disease research. In addition, Dr. Sudhir also worked on clinical research and medical affairs at various pharmaceutical companies, including
Millennium,
diaDexus, and
Johnson & Johnson, where he served as the
director of
Macroflux Internal Venture.
Dr. Sudhir received his
MD from
Madras Medical College and his
Ph.D. from
Monash University in Australia; he has received numerous honors for his academic excellence. He is also a Fellow of the
Royal Australasian College of Physicians, a member of the
American College of Cardiology, and the
Society of Cardiac Angiography and Intervention.
Regarding the board position with Pulnovo Medical,
Dr. Sudhir said, "I am proud to be joining as a member of the SAB to contribute to the technology development, commercialization, and research innovation of Pulnovo Medical. With a holistic approach to medical research, industry, research, production, and business management, Pulnovo Medical is at the forefront of medical research that will lead to innovative treatments for unmet clinical needs around the world. For patients with limited access to current therapies, these innovative treatments will certainly improve their health resilience. It is my privilege to be working with the Pulnovo Medical team to develop and explore new treatments to meet the urgent needs of patients and to create innovative and differentiated medical technologies together."
Pulnovo Medical, said, "On behalf of Pulnovo Medical and the Board of Directors, I welcome Dr. Krishna Sudhir in joining our Scientific Advisory Board. Dr. Sudhir is an outstanding scientist and industry leader. His excellent scientific foundation, strategic thinking, and business acumen will greatly enhance the innovation capabilities of Pulnovo Medical and will play a positive role in promoting the strategic layout of product pipelines and international collaboration to help take Pulnovo Medical to the next level.
About Pulnovo Medical
Since its inception in 2013, Pulnovo Medical has insisted on the importance of clinical value and has been committed to creating a global OTM innovation platform with its globally leading original technology. With more than 45 Chinese and international invention patents, we have developed a range of world-first products, entered the Green Channel of CFDA for innovative medical devices, and obtained CE quality system certification. In February 2021, we were granted the FDA breakthrough device designation for our original product — a radiofrequency ablation catheter. Insisting on innovation and aiming to improve patient recovery, we have, in a short time, become a leader in the interventional therapy of pulmonary arterial hypertension and will walk together with patients toward a better future with the support of our strong research and development capabilities.
SOURCE Pulnovo Medical
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.